Decision Resources is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.
Eli Lilly’s insulin peglispro is set to become the clinical gold-standard in the treatment of patients with type 2 diabetes inadequately controlled with diet and exercise, when metformin is not a therapeutic option... Learn More
Join us live on August 13, 2014... Learn More
View Webinar schedule and archive
See which reports have been searched on the most.
TreatmentTrends: Acute Kidney Injury (US) 2014
In this new report, both surveyed nephrologists and critical care physicians report that there is a high perceived need for new therapies for the treatment of acute kidney injury (AKI).
View sample slides from this report to learn more about our analysis of physicians’ practice patterns, attitudes and perceptions of projected use of various products in development for AKI.
July 23, 2014
Physicians in Brazil and Mexico Ideally Prefer Novel Oral Anticoagulants Such as Bayer/Janssen’s Xarelto Versus Conventional Anticoagulants for the Treatment of VTE, AF and ACS
July 21, 2014
The Alzheimer’s Disease Market Is Forecast to Reach Nearly $12 Billion by 2023, Following the Projected Launch of the First Disease-Modifying Therapies
Amgen’s Evolocumab is Set to Become the Clinical Gold-Standard Among Statin Add-On Therapies for Dyslipidemia
Multiple Sclerosis - 2014
Last Updated 23 July 2014The market for disease-modifying multiple sclerosis (MS) therapies is in the... Read More
Unipolar Depression - 2014
Last Updated 22 July 2014Unipolar depression—comprising major depressive disorder (MDD), minor... Read More
Psoriasis (Moderate to Severe)
Affecting more than 3 million people in the major pharmaceutical markets, moderate to severe psoriasis represents a... Read More